Objective:To assess the effects of the levonorgestrel-releasing intrauterine system (LNG-IUS) on standard cardiovascular risk markers among women with thrombophilia and/or previous venous thromboembolism (VTE).Methods: A prospective cohort study enrolled women aged 18-45 years with thrombophilia and/or a history of VTE who received the 52-mg LNG-IUS (20 μg/d initial release) at the University of Ribeirão Preto Medical School, Brazil, from January 2006 to December 2015. Before and 12 months after LNG-IUS placement, the following cardiovascular risk markers were assessed: lipid profile, body mass index (BMI), blood glucose, systolic blood pressure, diastolic blood pressure, and waist circumference. The primary outcome was changes in cardiovascular risk markers. A subanalysis of anticoagulant users versus non-users was also conducted.
Results:In total, 45 women were enrolled. BMI increased by 2.3% after 12 months of LNG-IUS placement (P < 0.01), but the other risk factors did not change. Cardiovascular risk markers were similar between anticoagulant users and non-users after 12 months of LNG-IUS use.Conclusion: Among women with thrombophilia and/or previous VTE, cardiovascular risk markers were not found to change significantly after 12 months of LNG-IUS use.The study adds safety information regarding use of the LNG-IUS for women at risk of thromboembolism.
K E Y W O R D SCardiovascular diagnostic techniques; Contraception; Intrauterine devices; Medicated intrauterine devices; Thrombophilia; Thrombosis
| INTRODUCTIONPregnancy, which is traditionally associated with a higher risk of venous thromboembolism (VTE), is also associated with a higher risk of complications, especially VTE recurrence, among women with a previous history of VTE and/or thrombophilia. 1,2 Therefore, the prevention of unplanned pregnancies for these women is extremely important, because VTE is one of the leading causes of maternal mortality. 3According to the WHO eligibility criteria for contraceptive use, women with a history of VTE or thrombophilia may use nonhormonal methods or progestogen-only contraceptives (POCs). 4This recommendation is based on evidence that most POCs are not non-hormonal contraceptives. 19 Both HDL-C and total cholesterol levels were lower in LNG-IUS users than in users of non-hormonal contraceptives even after adjusting for BMI. 19 In addition, a randomized clinical trial comparing lipid profile between copper intrauterine device (Cu-IUD) users and LNG-IUS users for 18 months found no negative effects of the LNG-IUS on lipid profile among healthy Asian women. 20In populations at risk of cardiovascular disease, such as obese individuals, 21,22 use of the LNG-IUS as compared with non-hormonal contraceptives (e.g., Cu-IUD) has previously presented reassuring results regarding cardiovascular risk markers. 21,22 In the present study, a slight increase in BMI after 12 months of LNG-IUS use was observed.However, a previous study found no difference in weight gain between A few studies have evaluated LNG-IUS use among women w...